Cytoreduction and HIPEC in the Netherlands : nationwide long-term outcome following the Dutch protocol
(2013) In Annals of Surgical Oncology 20(13). p.4224-4230- Abstract
PURPOSE: This nationwide study evaluated results of cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastasis of colorectal origin in the Netherlands following a national protocol.
METHODS: In a multi-institutional study prospective databases of patients with peritoneal carcinomatosis (PC) from colorectal cancer and pseudomyxoma peritonei (PMP) treated according to the Dutch HIPEC protocol, a uniform approach for the CRS and HIPEC treatment, were reviewed. Primary end point was overall survival and secondary end points were surgical outcome and progression-free survival.
RESULTS: Nine-hundred sixty patients were included; 660 patients (69 %) were affected by PC of... (More)
PURPOSE: This nationwide study evaluated results of cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastasis of colorectal origin in the Netherlands following a national protocol.
METHODS: In a multi-institutional study prospective databases of patients with peritoneal carcinomatosis (PC) from colorectal cancer and pseudomyxoma peritonei (PMP) treated according to the Dutch HIPEC protocol, a uniform approach for the CRS and HIPEC treatment, were reviewed. Primary end point was overall survival and secondary end points were surgical outcome and progression-free survival.
RESULTS: Nine-hundred sixty patients were included; 660 patients (69 %) were affected by PC of colorectal carcinoma and the remaining suffered from PMP (31 %). In 767 procedures (80 %), macroscopic complete cytoreduction was achieved. Three-hundred and thirty one patients had grade III-V complications (34 %). Thirty-two patients died perioperatively (3 %). Median length of hospital stay was 16 days (range 0-166 days). Median follow-up period was 41 months (95 % confidence interval (CI), 36-46 months). Median progression-free survival was 15 months (95 % CI 13-17 months) for CRC patients and 53 months (95 % CI 40-66 months) for PMP patients. Overall median survival was 33 (95 % CI 28-38 months) months for CRC patients and 130 months (95 % CI 98-162 months) for PMP patients. Three- and five-year survival rates were 46 and 31 % respectively in case of CRC patients and 77 and 65 % respectively in case of PMP patients.
CONCLUSIONS: The results underline the safety and efficacy of cytoreduction and HIPEC for PC from CRC and PMP. It is assumed the uniform Dutch HIPEC protocol was beneficial.
(Less)
- author
- publishing date
- 2013
- type
- Contribution to journal
- publication status
- published
- keywords
- Adenocarcinoma, Mucinous/mortality, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Carcinoma, Signet Ring Cell/mortality, Chemotherapy, Cancer, Regional Perfusion, Colorectal Neoplasms/mortality, Female, Follow-Up Studies, Humans, Hyperthermia, Induced, Male, Middle Aged, Neoplasm Staging, Netherlands, Peritoneal Neoplasms/mortality, Prognosis, Prospective Studies, Survival Rate, Young Adult
- in
- Annals of Surgical Oncology
- volume
- 20
- issue
- 13
- pages
- 4224 - 4230
- publisher
- Springer
- external identifiers
-
- scopus:84892374282
- pmid:23897008
- ISSN
- 1534-4681
- DOI
- 10.1245/s10434-013-3145-9
- language
- English
- LU publication?
- no
- id
- 6edcd785-9aa4-4107-8651-35e3520b8ac7
- date added to LUP
- 2022-04-05 11:14:36
- date last changed
- 2024-04-10 04:50:33
@article{6edcd785-9aa4-4107-8651-35e3520b8ac7,
abstract = {{<p>PURPOSE: This nationwide study evaluated results of cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastasis of colorectal origin in the Netherlands following a national protocol.</p><p>METHODS: In a multi-institutional study prospective databases of patients with peritoneal carcinomatosis (PC) from colorectal cancer and pseudomyxoma peritonei (PMP) treated according to the Dutch HIPEC protocol, a uniform approach for the CRS and HIPEC treatment, were reviewed. Primary end point was overall survival and secondary end points were surgical outcome and progression-free survival.</p><p>RESULTS: Nine-hundred sixty patients were included; 660 patients (69 %) were affected by PC of colorectal carcinoma and the remaining suffered from PMP (31 %). In 767 procedures (80 %), macroscopic complete cytoreduction was achieved. Three-hundred and thirty one patients had grade III-V complications (34 %). Thirty-two patients died perioperatively (3 %). Median length of hospital stay was 16 days (range 0-166 days). Median follow-up period was 41 months (95 % confidence interval (CI), 36-46 months). Median progression-free survival was 15 months (95 % CI 13-17 months) for CRC patients and 53 months (95 % CI 40-66 months) for PMP patients. Overall median survival was 33 (95 % CI 28-38 months) months for CRC patients and 130 months (95 % CI 98-162 months) for PMP patients. Three- and five-year survival rates were 46 and 31 % respectively in case of CRC patients and 77 and 65 % respectively in case of PMP patients.</p><p>CONCLUSIONS: The results underline the safety and efficacy of cytoreduction and HIPEC for PC from CRC and PMP. It is assumed the uniform Dutch HIPEC protocol was beneficial.</p>}},
author = {{Kuijpers, Anke M J and Mirck, Boj and Aalbers, Arend G J and Nienhuijs, Simon W and de Hingh, Ignace H J T and Wiezer, Martinus J and van Ramshorst, Bert and van Ginkel, Robert J and Havenga, Klaas and Bremers, Andreas J and de Wilt, Johannes H W and Te Velde, Elisabeth A and Verwaal, Vic J}},
issn = {{1534-4681}},
keywords = {{Adenocarcinoma, Mucinous/mortality; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Carcinoma, Signet Ring Cell/mortality; Chemotherapy, Cancer, Regional Perfusion; Colorectal Neoplasms/mortality; Female; Follow-Up Studies; Humans; Hyperthermia, Induced; Male; Middle Aged; Neoplasm Staging; Netherlands; Peritoneal Neoplasms/mortality; Prognosis; Prospective Studies; Survival Rate; Young Adult}},
language = {{eng}},
number = {{13}},
pages = {{4224--4230}},
publisher = {{Springer}},
series = {{Annals of Surgical Oncology}},
title = {{Cytoreduction and HIPEC in the Netherlands : nationwide long-term outcome following the Dutch protocol}},
url = {{http://dx.doi.org/10.1245/s10434-013-3145-9}},
doi = {{10.1245/s10434-013-3145-9}},
volume = {{20}},
year = {{2013}},
}